Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477006 | 0.84 | ALDH1A1 (0.59) | ALDH1A1TSHRHTTABCB1KDM4E | |
| SCHEMBL3339926 | 0.84 | ABCB1 (0.64) | ALDH1A1TSHRHTTABCB1KDM4E | |
| SCHEMBL13763533 | 0.83 | HTT (0.71) | ALDH1A1TSHRHTTABCB1KDM4E | |
| Benzene SCHEMBL28043964 | 0.83 | ALDH1A1 (0.57) | ALDH1A1TSHRHTTABCB1KDM4E | |
| Bicarbonate SCHEMBL20694841 | 0.83 | ALDH1A1 (0.57) | ALDH1A1TSHRHTTABCB1KDM4E | |
| Bicarbonate SCHEMBL236893 | 0.83 | ALDH1A1 (0.57) | ALDH1A1TSHRHTTABCB1KDM4E | |
| SCHEMBL17799583 | 0.83 | ALDH1A1 (0.57) | ALDH1A1TSHRHTTABCB1KDM4E | |
| Bicarbonate SCHEMBL29943829 | 0.83 | ALDH1A1 (0.57) | ALDH1A1TSHRHTTABCB1KDM4E | |
| SCHEMBL385218 | 0.81 | ALDH1A1 (0.54) | ALDH1A1TSHRHTTLMNASMN1; SMN2 | |
| SCHEMBL17799584 | 0.81 | HTT (0.53) | ALDH1A1TSHRHTTABCB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723691-B2 | Process for preparing salicyloyl-L-carnitine hydrochloride | DRUG'ON PHARMA SWITZERLAND AG (CH) | 2020-07-28 | — | — | US | disclosed |
| EP-3507271-A1 | PROCESS FOR PREPARING SALICYLOYL-L-CARNITINE HYDROCHLORIDE | Drug'On Pharma Switzerland AG (CH) | 2019-07-10 | — | — | EP | disclosed |
| US-20190202775-A1 | PROCESS FOR PREPARING SALICYLOYL-L-CARNITINE HYDROCHLORIDE | DRUG'ON PHARMA SWITZERLAND AG (CH) | 2019-07-04 | — | — | US | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| CN-1423647-A | Beta-alanine derivatives and their use as receptor antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-06-11 | — | — | CN | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| US-4960943-A | ACYLATING REACTION IN THE PRESENCE OF ZEOLITE CATALYSTS | BAYER AKTIENGESELLSCHAFT (DE) | 1990-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202775-A1 | PROCESS FOR PREPARING SALICYLOYL-L-CARNITINE HYDROCHLORIDE | CRAT, CPT1B, MCCC2 | ALDH1A1 859/4885TSHR 3640/4885HTT 2207/4885 |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | ALDH1A1 578/4885TSHR 689/4885HTT 3050/4885 |
| US-10723691-B2 | Process for preparing salicyloyl-L-carnitine hydrochloride | CRAT, CPT1B, MCCC2 | ALDH1A1 859/4885TSHR 3640/4885HTT 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.